Characteristics and outcomes of Parkinson’s disease individuals hospitalized with COVID-19 in a New York City hospital system
Objective: To determine the clinical characteristics and outcomes in hospitalized individuals with Parkinson's disease (PD) infected with COVID-19 Background: The COVID-19 pandemic has caused worse…Evaluation of Care delivery model for integrated care and self-management for people with Parkinson’s disease with Deep Brain Stimulation
Objective: To evaluate the implementation and impact potential of a pragmatic network for PD care, the Integrated Parkinson Care Network (IPCN) for patients with chronic…Tele and video consultations of patients with parkinsonism in the Brazilian public health system – a real life feasibility study
Objective: To evaluate the feasibility and identify obstacles in conducting teleconsultations for patients with parkinsonism in the Brazilian public health system Background: Patients with parkinsonism…Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months
Objective: Results from cohort 2 in the Phase 1/2 SUNRISE-PD study (NCT03720418) at 6 months (6M) post administration of AXO-Lenti-PD (ALPD) gene therapy are presented.…Cinpanemab in Parkinson’s Disease: Imaging and Fluid Biomarker Results from the Phase 2 SPARK Study
Objective: To evaluate the effects of cinpanemab on biomarkers in participants with Parkinson’s disease (PD). Background: SPARK (NCT03318523) was designed to evaluate the safety, pharmacokinetics,…The Hauser Diary knowledge test as a tool to improve Rater Training Programs in Parkinson’s disease clinical trials
Objective: To identify the areas with specific training needs for Rater Training Programs (RTP) on the Hauser Diary in Parkinson’s disease (PD) clinical trials Background:…Secondary endpoints of a randomized, placebo-Controlled Pilot Study to evaluate the safety of lyophilized PRIM-DJ2727 in Parkinson’s disease
Objective: To evaluate the impact of fecal microbiome transplant (FMT) on disease progression as a secondary outcome of a safety study using PRIM-DJ2727 in Parkinson's…The EON (Elderly patients on ONgentys) study in Parkinson’s disease: design and rationale of a prospective non-interventional trial
Objective: To assess the tolerability of opicapone (OPC) when used in elderly patients with Parkinson’s disease (PD) in real-world conditions. Background: OPC proved to be…Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
Objective: To assess the influence of a 6-month treatment with opicapone (OPC) on the costs for the care of Parkinson’s disease (PD) patients. Background: OPC…Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial
Objective: To assess the long-term effectiveness of LCIG monotherapy on reducing daily health-state fluctuations and time to on without troublesome dyskinesia (ONwoTD) after waking Background:…
- « Previous Page
- 1
- …
- 299
- 300
- 301
- 302
- 303
- …
- 338
- Next Page »